High-dose interferon-α therapy lowers the levels of serum fibrogenesis markers over 5 years in chronic hepatitis C

Abe, Shintaro; Tabaru, Akinari; Ono, Masami; Tai, Mayumi; Narita, Ryouichi; Moriyama, Atsushi; Ōtsuki, Makoto

doi:10.1016/s1386-6346(02)00203-6

Cited by 13 publications

(7 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, we found significant association in evolution of fibrosis after treatment with PEG-IFN α2a (40) kD and PEG-IFNα2b (12,5) kD with ribavirin (p=0.000, p<0.05) (Table 4). Similar results have been found in other studies (16, 17, 18,19) i.e. there is growing clinical evidence that fibrosis can regress and possibly even resolve in a number of liver diseases.…”

Section: Discussionsupporting

confidence: 91%

Analysis of Effect of Antiviral Therapy on Regression of Liver Fibrosis in Patient with HCV Infection

et al. 2014

View full text Add to dashboard Cite

Background:HCV infection is characterized by a tendency towards chronicity. Acute HCV infection progresses to chronic infection in 70% of cases. Hepatitis C virus infection can cause progressive liver injury and lead to fibrosis and eventually cirrhosis. The degree of histologic fibrosis is an important marker of the stage of the disease. One of current standard treatment for CHC infection is the combination of PEG-IFN α and ribavirin.Objectives:The aim of the study was to investigate the effect of the therapy with Peginterferon alfa-2a or alfa-2b plus Ribavirin on evolution of liver fibrosis in patients with chronic hepatitis C. Also, our aim was to examine whether there was a difference between the genders in the efficacy of these antiviral therapy. Our goal also was to determine effect of the therapy with Peginterferon alfa-2a or alfa-2b plus Ribavirin on evolution of liver steatosis in patients with chronic hepatitis C.Patients and Methods:A retrospective study was made of chronic hepatitis C patients who had been treated from 2005 to April 2014 at the Clinic of Gastroenterohepatology, Clinical Center University of Sarajevo. We reviewed 40 patient medical records to collect demographic, epidemiological and clinical information, as information on liver biopsies that was performed prior to the antiviral therapy and FibroScan® test that was performed after the antiviral therapy. For the processing of data SPSS (Statistical Package for the Social Sciences Program) for Windows, ver. 21.0 statistical software was used. Comparisons between qualitative and quantitative variables were performed using the Student t-test. Mann Whitney U test was used to compare differences in variables such as fibrosis stage and steatosis grade. A value of p<0.05 was considered as statistically significant.Results:After treatment, there was a statistically significant increase in the number of patients with no fibrosis (p<0.05). There was no statistically significant reduction in the number of patients with cirrhosis (F4) (p>0.05). There was significantly higher decrease of fibrosis progression at the patients that were in an mild-to-moderate fibrosis (F1/F2/F3), patients that were in advanced stage of fibrosis (F4) at the time of the pre-treatment did not have a statistically significant fibrosis reduction. We found significant association in evolution of fibrosis after treatment with PEG-IFN α2a (40) kD and PEG-IFNα2a (12,5) kD with ribavirin (p< 0.05). We also found significant association in evolution of steatosis after treatment with PEG-IFN α2a (40) kD and PEG-IFNα2a (12,5) kD with ribavirin (p < 0.05). There was statistically significant differences (p<0.05) between genders within fibrosis qualitative evolution.Conclusions:There were significant regression of fibrosis especially at the patients that were in an mild-to-moderate fibrosis (F1/F2/F3), patients that were in advanced stage of fibrosis (F4) at the time of the pre-treatment did not have a statistically significant fibrosis reduction after treatment with PEG-IFN α2a (40) ...

show abstract

Section: Discussionsupporting

confidence: 91%

Analysis of Effect of Antiviral Therapy on Regression of Liver Fibrosis in Patient with HCV Infection

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The attained data on the dynamics of liver fibrosis after AVT is consistent with the results of other researchers, who believe that even after the HCV eradication, an increased activity of perisinusoidal Ito cells and expression of proteins (Bcl-2) -apoptotic inhibitors that support fibrogenesis, mono-and polyclonal proliferation of astrocytes and B-lymphocytes with a high risk of B cell neoplasia and HCC, may remain unchanged [10] . Additionally, endogenous (steatosis) and exogenous (toxic-alimentary) factors can contribute to cirrhosis development.…”

Section: Discussionsupporting

confidence: 90%

Virological and Morphological Efficiency of Different Anti-Virus Therapeutic Regimens for Patients With Chronic Hepatitis C

Iosyk

Andreychyn

Ивахив

et al. 2019

Journal of Gastroenterology and Hepatology Research

View full text Add to dashboard Cite

INTRODUCTION: Chronic hepatitis C (CHC) is a topical medical and social issue in Ukraine, despite of the high effectiveness of present antiviral therapy (AVT). The aim of the research is to evaluate the virological and morphological effectiveness of various therapeutic regimens of AVT in cases of CHC. MATERIALS AND METHODS: 160 patients with CHC underwent AVT. Liver fibrosis (F) was evaluated using a fibro-test before and after treatment. According to the AVT therapeutic regimens the patients were divided into the following groups: group 1 (51 patients)-pegylated interferon-α (PEG-IFN) and ribavirin for 24-48 weeks; group 2 (34 patients)-sofosbuvir as well for 12 weeks; group 3 (74 patients) no PEG-IFN 12-week therapeutic regimen: sofosbuvir and ribavirin (2 patients), direct antiviral drugs (DAD): sofosbuvir and lepipasvir (48 patients), sofosbuvir and daclatasvir (11 patients), and ribavirin as well (9 patients) for 24 weeks, sofosbuvir and velpatasvir (3 patients), together with ribavirin (1 patient), 3D therapy (ombitasvir/paritaprevir/ritonavir + dasabuvir) (1 patient). RESULTS: In the group 1, a stable viral response (SVR) in 12 and 24 weeks was evidenced in 78.4% of the patients, in the group 2-in 97.0%, in the group 3-in 98.7%. A number of people with the most severe inflammatory and necrotic processes in the liver fibrosis (F3) decreased from 41.6 to 9.7% (p < 0.02) at the end of the treatment in the presence of a significantly increased frequency of F0 (up to 84.6%). After treatment, in 61 examined patients, liver fibrosis reduction was evidenced in 54.1%, in 36.1% the degree of fibrosis did not change, and in 9.8%-fibrosis expansion was present. CONCLUSIONS: Eradication of HCV does not ensure further progression of liver fibrosis.

show abstract

“…These markers are often very high in active inflammatory states of the liver, such as alcoholic hepatitis, and are often more elevated than in patients with less active cirrhosis 18. Similarly, in some studies, their levels have been shown to fall with successful interferon therapy prior to any expected reduction in the hepatic fibrosis stage 19–22. Although we did not find high levels of inflammatory activity in the first biopsy specimens, we did find that the markers were highly predictive of early fibrosis progression.…”

Section: Discussioncontrasting

confidence: 55%

Serum fibrosis markers can predict rapid fibrosis progression after liver transplantation for hepatitis C

et al. 2008

View full text Add to dashboard Cite

Although recurrent hepatitis C virus (HCV) after liver transplantation (LT) is universal, a minority of patients will develop cirrhosis within 5 years of surgery, which places them at risk for allograft failure. This retrospective study investigated whether 2 serum fibrosis markers, serum hyaluronic acid (HA) and YKL-40, could be used to predict rapid fibrosis progression (RFP) post-LT. These markers were compared with conventional laboratory tests, histological assessment, and hepatic stellate cell activity (HSCA), a key step in fibrogenesis, as assessed by immunohistochemical staining for alpha-smooth muscle actin. Serum and protocol liver biopsy samples were obtained from 46 LT recipients at means of 5 Ϯ 2 (biopsy 1) and 39 Ϯ 6 (biopsy 2) months post-LT, respectively. RFP was defined as an increase in the fibrosis score Ն 2 from biopsy 1 to biopsy 2 (a mean interval of 33 Ϯ 6 months). The ability of parameters at biopsy 1 to predict RFP was compared with the areas under receiver operating characteristic curves (AUROCs). Of the 46 subjects, 15 developed RFP. Serum HA and YKL-40 performed significantly better than conventional parameters and HSCA in predicting RFP post-LT for HCV at biopsy 1, with AUROCs of 0.89 and 0.92, respectively. The accuracy of serum HA Ն 90 g/L and YKL-40 Ն 200 g/L in predicting RFP at biopsy 1 was 80% and 96%, respectively. In conclusion, we found that elevated levels of serum HA and YKL-40 within the first 6 months after LT accurately predicted RFP. See Editorial on Page 1237End-stage liver disease from chronic hepatitis C virus (HCV) infection is the leading indication for liver transplantation (LT) in the United States. Although virologic recurrence of HCV is universal, the histologic and clinical course of HCV after LT is highly variable.1 Progression to cirrhosis occurs in 6% to 23% of patients at a median of 3 to 4 years post-LT. 1 Several donor, recipient, viral, and transplant-related factors have been associated with more severe recurrent HCV disease after transplantation.2,3 Efforts to identify individuals at risk for rapid fibrosis progression (RFP) have included histological assessment of allograft biopsies, measurement of liver stiffness by transient elastography (TEG),

show abstract

High-dose interferon-α therapy lowers the levels of serum fibrogenesis markers over 5 years in chronic hepatitis C

Cited by 13 publications

References 32 publications

Analysis of Effect of Antiviral Therapy on Regression of Liver Fibrosis in Patient with HCV Infection

Analysis of Effect of Antiviral Therapy on Regression of Liver Fibrosis in Patient with HCV Infection

Virological and Morphological Efficiency of Different Anti-Virus Therapeutic Regimens for Patients With Chronic Hepatitis C

Serum fibrosis markers can predict rapid fibrosis progression after liver transplantation for hepatitis C

Contact Info

Product

Resources

About